PAVM vs YI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
PAVM exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9 and a catastrophic Current Ratio of 0.17, indicating a severe liquidity crisis. While revenue growth is nominally high (420%), the operational efficiency is non-existent with an operating margin of -13,082.69% and negative gross margins. There is a profound disconnect between the fundamental collapse (99.5% 5-year price decline) and the optimistic analyst target price of $40.50. The company is currently operating in a state of extreme financial fragility with no evidence of sustainable profitability.
YI presents a high-risk profile characterized by a stable Piotroski F-Score (5/9) that masks severe underlying fundamental decay. The most critical red flag is a negative Price/Book ratio (-0.60), indicating negative shareholders' equity and potential insolvency. This is compounded by a significant revenue contraction of -26.70% YoY and a poor Quick Ratio of 0.45, suggesting severe liquidity constraints. Despite a speculative 6-month price bounce, the lack of analyst coverage and bearish technical trend (0/100) suggest a lack of institutional support.
Compare Another Pair
Related Comparisons
PAVM vs YI: Head-to-Head Comparison
This page compares PAVmed Inc. (PAVM) and 111, Inc. (YI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.